01Material
What is the source?
Cell type, donor or tissue origin, culture medium and collection conditions must be specified.
Exosome-Based Approaches · Hair and Scalp · Istanbul
Exosome-Based Approaches · Hair and Scalp · Istanbul
Exosome-Based Approaches
An exosome claim does not identify a clinical product. Source cells, culture conditions, separation and purification, accompanying material, sterility, batch release, storage and intended route determine what is actually being considered.
Exosomes are not stem cells. If endosomal origin has not been demonstrated, the broader term extracellular vesicles may be more accurate; neither term promises regeneration or hair growth.
Quick Orientation
Four questions before any exosome-based discussion
Move from a market label to an identifiable preparation.
Particle numbers or a certificate alone do not establish identity, purity, authorisation or clinical relevance.
02Manufacture
How was it produced?
Separation, enrichment, purification, formulation, filling and storage form one traceable chain.
03Release
What is in the batch?
Complementary tests should address vesicle identity, non-vesicular material, sterility and contaminants.
04Evidence
Which data apply?
Only evidence using a comparable source, product, route, target tissue and endpoint is relevant.
Product Identity
Cell-free vesicles · source- and process-dependent
Not every small extracellular particle is an exosome.
Cells release several types of extracellular vesicle. Exosome is a biogenesis term; size or one surface marker cannot establish that origin by itself.
What can be established
- Describe a cell-free preparation with a stated source and manufacturing route
- Characterise a specific batch using complementary analytical methods
- Evaluate one preparation for one defined scalp or skin question
- Document product status, route, tolerability and a pre-agreed endpoint
What must not be inferred
- Call the preparation a living stem-cell treatment
- Assume conditioned medium, purified vesicles and plant particles are interchangeable
- Infer purity or potency from particle count alone
- Promise regeneration, new follicles, density or lasting growth
Exosome is not a quality mark or authorisation category. Unclear source, manufacture, characterisation, sterility or legal status is a reason not to proceed.
Medical Suitability
Diagnosis, product dossier and route together
Five checks precede any product decision.
An online pre-assessment may organise the question. It cannot verify a batch, diagnose the scalp or determine whether a route is lawful and medically appropriate.
- 01
Define the diagnosis
Pattern loss is separated from sudden, inflammatory, scarring or otherwise unexplained hair loss.
- 02
Examine the target tissue
Barrier disruption, infection, inflammation, scarring and anatomical injection risks are assessed in person.
- 03
Review the dossier
Source, culture, purification, composition, sterility, batch, storage and release documents are checked.
- 04
Review personal risk
Medical history, medicines, allergies, immune factors, pregnancy and healing risks may alter suitability.
- 05
Compare other options
Authorised therapy, observation, another procedure or no treatment is weighed against the uncertainty.
Manufacture and Route
Source · separation · release
The production chain is part of the product identity.
Culture, removal of cells and debris, vesicle enrichment, purification, analytical release and cold-chain control must remain connected.
01Starting material
Cells and culture
The source bank, donor screening, culture medium and collection window define the starting material.
- Identify source and donor controls
- Record culture and harvest conditions
- Exclude undeclared animal or human components
02Preparation
Separation and characterisation
The method determines vesicle recovery and the amount of non-vesicular material that remains.
- State enrichment and purification steps
- Use complementary identity tests
- Check sterility, endotoxin and contamination
03Clinical release
Status, storage and route
A traceable batch requires documented release, shelf life, handling and one intended clinical route.
- Verify batch and storage history
- Separate topical, channel-assisted and injected use
- Record region, route and observed events
A cosmetic label, laboratory report, CE mark or high particle count does not by itself establish permission, sterility, safety or clinical effectiveness for a medical use.
Evidence and Limits
Early human studies · substantial heterogeneity
Findings cannot be transferred between unlike products.
Published human work remains early and uses different sources, preparations, routes and endpoints. Long-term safety and comparative effectiveness are not established as a class effect.
Read hair studies narrowly
Small studies cannot establish a general scalp protocol or apply to every cause of hair loss.
Keep skin data separate
A short-term skin endpoint does not prove a hair outcome or general rejuvenation.
Do not transfer routes
Use on intact skin, after microneedling and by injection have different exposure and risks.
Check current regulation
Regulatory warnings about unapproved products make product-specific status central to the decision.
Laboratory activity or an early clinical signal does not establish a standard treatment, superiority, a session number or a predictable personal response.
Individual Plan
A dossier before a session
A plan begins with a defined product and review point.
No package is set by particle count. The indication, status, route, uncertainty and measurable endpoint must first support a limited decision.
Document the baseline
Diagnosis, target region, photographs, endpoint, medicines and standard options are recorded.
Complete product review
Source, manufacture, release, sterility, batch, storage and authorisation remain visible.
Limit the first decision
If consideration is defensible, one product, route, target and follow-up point are specified.
Reassess independently
Safety, objective findings, burden and alternatives determine whether any further step is justified.
Course and Follow-Up
Application reaction · product safety · clinical endpoint
Early redness is not evidence of vesicle uptake or benefit.
Immediate tolerability and a later hair or skin endpoint require separate timeframes and comparable documentation.
- 01Day of use
Record the exposure
Product, batch, route, region and immediate burning, redness, swelling or bruising are documented.
- 02Early safety
Review unexpected reactions
Persistent inflammation, infection, allergy, nodules or systemic symptoms require clinical assessment.
- 03Clinical review
Measure the agreed target
Only the pre-defined hair or skin feature is compared under consistent conditions.
- 04Decision
Apply the stop rule
Unclear safety or no objective signal does not justify automatic repetition or a different unverified batch.
Risks and Alternatives
Cell-free does not mean risk-free
Source, contaminants and route shape the risk profile.
Local procedure risks sit alongside uncertainty about donor material, residual proteins or nucleic acids, endotoxin, microbes, storage failure and biological activity.
01Procedure
Route and region
Pain, bleeding, bruising, inflammation, infection and injection-related anatomical injury vary by route.
02Product
Product and batch
Residual material, foreign proteins, contamination, immune reaction or unknown cargo may be relevant.
03Alternative
Other strategy
Authorised medical treatment, observation, a better-supported procedure or no treatment may be preferable.
04Decision
Withhold or stop
Treatment is withheld or stopped when the indication, consent, safety controls or follow-up cannot support a proportionate plan.
Product traceability and a clear post-treatment contact route are essential; unexpected local or general symptoms are assessed in relation to the exact batch and route.
Istanbul and Follow-Up
Product review before travel
A product question continues beyond the treatment day.
International planning connects the medical question, original product documentation, in-person examination and a realistic route for later review.
01Before travel
Organise the question
History, previous care, medicines and comparable photographs prepare the medical discussion.
02In Istanbul
Examine and verify
Diagnosis, tissue, dossier, status, route, risks and alternatives are considered together.
03Treatment day
Keep traceability
Any use would retain product, batch, storage, route, region and immediate observations.
04After return
Make review possible
Aftercare, warning signs, contact pathway and the endpoint review are arranged before departure.
The Doctor Aslan Approach
Identity · purity · route · evidence boundary
The complete product chain matters more than the trend term.
An exosome-based offer is not described as stem-cell treatment or general regeneration. Source, manufacture, batch release, route and relevant human evidence must all be coherent.
Use precise names
Extracellular vesicle is preferred when exosomal origin has not been established.
Review the dossier
Source, processing, characterisation, sterility, storage and status stay visible.
Separate target and route
Scalp, skin, intact barrier, microchannels and injection are not interchangeable.
Define a stop rule
Unclear identity, status, safety or objective purpose argues against starting or continuing.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about exosomes and extracellular-vesicle preparations; no personal diagnosis, protocol or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Exosome-Based Approaches?+
Exosome-Based Approaches is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Exosome-Based Approaches?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Identify the product · define the indication